Rigel Pharma not quite there with European application for fostamatinib [Seeking Alpha]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Seeking Alpha
Seeking Alpha Healthcare Rigel Pharma not quite there with European application for fostamatinib Oct. 18, 2019 7:52 AM ET | Rigel Pharmaceuticals,... (RIGL) Douglas W. House Despite announcing a lineup of positive opinions today, the European Medicines Agency's advisory group CHMP could only muster a " positive trend vote Rigal chief Raul Rodriguez says, "During the EMA review process for fostamatinib in adult chronic ITP, we have had very constructive interactions with the committee. We are pleased with this positive trend vote from the CHMP this week, which brings us one step closer to potentially providing a new therapeutic option for a patient population that has a clear unmet clinical need." CHMP should issue a final opinion at next month's meeting. Click to subscribe to real-time analytics on RIGL Now read: Heron Therapeutics (HRTX) Investor Presentation - Slideshow » Subscribe
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdatePR Newswire
- Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy [Seeking Alpha]Seeking Alpha
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma [Yahoo! Finance]Yahoo! Finance
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaPR Newswire
RIGL
Earnings
- 3/5/24 - Beat
RIGL
Sec Filings
- 4/12/24 - Form 8-K
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- RIGL's page on the SEC website